Skip to main content

May 2022, Vol 12, No 5

The PD-1/CTLA-4 bispecific antibody, AK104, plus chemotherapy represents a potential new first-line treatment option for patients with advanced gastric or gastroesophageal junction (GEJ) cancer. Read More ›

First-line chemotherapy is the standard of care for advanced esophageal SCC, but survival outcomes are poor. First-line combination immunotherapy with the PD-1 inhibitor nivolumab (Opdivo) plus the CTLA-4 inhibitor ipilimumab (Yervoy) led to longer overall survival (OS) than chemotherapy or nivolumab monotherapy in solid tumors. Read More ›

Second-line standard therapy for patients with relapsed or refractory large B-cell lymphoma is high-dose chemotherapy and autologous stem-cell transplantation (ASCT), but the prognosis after first-line therapy is poor for many patients, who are unable to receive definitive therapy. Read More ›


At the 2022 Cholangiocarcinoma Foundation (CCF) Annual Conference on Melinda Bachini, Director of Advocacy of CCF, provided an update on the foundation’s advocacy and patient support initiatives. Read More ›

The International Cholangiocarcinoma Research Network (ICRN) is a program initiated by the Cholangiocarcinoma Foundation (CCF). The core mission of this network of international experts is “to rapidly translate scientific discoveries into practice for cholangiocarcinoma patients through a collaborative, highly translational international research network. Read More ›

It is no secret that the past 2 years have brought about major changes, not only in our personal lives, but in the ways that we manage our practices. Read More ›

Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many pharmacy benefit managers and health plans have been slow to prioritize biosimilars, leaving savings on the table. Read More ›

On April 14, 2022, the FDA released a new draft guidance to industry for increasing racial and ethnic diversity in clinical trials. Read More ›

Updates to the screening guidelines for colorectal cancer (CRC) from the National Comprehensive Cancer Network (NCCN) include lowering the initial screening age for average-risk individuals and second- and third-degree family members with CRC, as well as an extension in the interval for surveillance colonoscopy for low-risk individuals. Read More ›

Page 1 of 2